Name: The Future of Pharma: Evolutionary Threats and Opportunities (en Inglés)
Price: 2327.53 MXN
Availability: InStock
Author: Smith, Brian D.
ISBN: 9781409430315

Envío gratis

portada The Future of Pharma: Evolutionary Threats and Opportunities (en Inglés)

Formato

Libro Físico

Autor

Brian D. Smith

Editorial

Routledge

Año

2011

Idioma

Inglés

N° páginas

214

Encuadernación

Tapa Dura

Dimensiones

24.8 x 17.4 x 2.0 cm

Peso

0.63 kg.

ISBN13

9781409430315

Categorías

Estrategia empresarial
Gestión de proyectos de investigación y desarrollo
La industria farmacéutica

The Future of Pharma: Evolutionary Threats and Opportunities (en Inglés)

Brian D. Smith (Autor) · Routledge · Tapa Dura

Libro Físico

$ 2,327.53

$ 4,655.06

Ahorras: $ 2,327.53

50% descuento

Envío normal

Origen: Reino Unido (Costos de importación incluídos en el precio)

Se enviará desde nuestra bodega entre el Miércoles 19 de Junio y el Lunes 01 de Julio.

Lo recibirás en cualquier lugar de México entre 1 y 3 días hábiles luego del envío.

Reseña del libro "The Future of Pharma: Evolutionary Threats and Opportunities (en Inglés)"

By any standard, the pharmaceutical industry's history has been a successful one. In addition to its profits and shareholder dividends, it has been seen by investors as relatively low risk and, largely, counter-cyclical to stock market trends. However, that important contribution appears to be petering out, with significant global implications for employees, shareholders, governments and patients. This is not just caused by the economic crisis. Long before this, several distinct but related streams of evidence emerged that now point to the stalling of the pharmaceutical industry. The Future of Pharma examines the causes of the industry's potential decline and offers a convincing and rigorous analysis of the options open to it. What emerges is a landscape defined, on the one hand, by the changing marketplace of mass-market consumers, institutional healthcare systems and wealthy individuals; and on the other by the alternate sources of commercial value - innovative therapies; super-efficient processes, supply chains and operations; and closer customer relations and increasingly tailored health services. The challenges to the pharmaceutical industry now and in the medium and long-term are very significant. Brian Smith's highly readable research findings are a wake-up call and a first step forward for anyone concerned with the future of the industry; whether executive, customer, policymaker or investor.